{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:58:39Z","timestamp":1791363519767,"version":"4.3.1"},"reference-count":37,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2021,9,1]]},"DOI":"10.1001\/jamadermatol.2021.2599","type":"journal-article","created":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T15:01:16Z","timestamp":1626879676000},"page":"1056","source":"Crossref","is-referenced-by-count":103,"title":["Association Between Biologics Use and Risk of Serious Infection in Patients With Psoriasis"],"prefix":"10.1001","volume":"157","author":[{"given":"Laetitia","family":"Penso","sequence":"first","affiliation":[{"name":"Groupement d\u2019int\u00e9r\u00eat scientifique Epid\u00e9miologie des produits de sant\u00e9, L\u2019Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9\u2013Caisse Nationale de l'Assurance Maladie, Paris, France"},{"name":"Epid\u00e9miologie en Dermatologie et Evaluation des Th\u00e9rapeutiques, Universit\u00e9 Paris\u2013Est Creteil, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary","family":"Dray-Spira","sequence":"additional","affiliation":[{"name":"Groupement d\u2019int\u00e9r\u00eat scientifique Epid\u00e9miologie des produits de sant\u00e9, L\u2019Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9\u2013Caisse Nationale de l'Assurance Maladie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Weill","sequence":"additional","affiliation":[{"name":"Groupement d\u2019int\u00e9r\u00eat scientifique Epid\u00e9miologie des produits de sant\u00e9, L\u2019Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9\u2013Caisse Nationale de l'Assurance Maladie, Paris, France"},{"name":"Caisse Nationale d\u2019Assurance Maladie des Travailleurs Salari\u00e9s, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Pina Vegas","sequence":"additional","affiliation":[{"name":"Epid\u00e9miologie en Dermatologie et Evaluation des Th\u00e9rapeutiques, Universit\u00e9 Paris\u2013Est Creteil, Cr\u00e9teil, France"},{"name":"D\u00e9partement de Rhumatologie, Assistance Publique\u2013H\u00f4pitaux de Paris, H\u00f4pitaux universitaires Henri Mondor, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Zureik","sequence":"additional","affiliation":[{"name":"Groupement d\u2019int\u00e9r\u00eat scientifique Epid\u00e9miologie des produits de sant\u00e9, L\u2019Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9\u2013Caisse Nationale de l'Assurance Maladie, Paris, France"},{"name":"INSERM, Echappement aux anti-infectieux et Pharmaco\u00e9pid\u00e9miologie, Centre de recherche en \u00e9pid\u00e9miologie et sant\u00e9 des populations, Universit\u00e9 de Versailles Saint-Quentin-en-Yvelines, Montigny le Bretonneux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Sbidian","sequence":"additional","affiliation":[{"name":"Groupement d\u2019int\u00e9r\u00eat scientifique Epid\u00e9miologie des produits de sant\u00e9, L\u2019Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9\u2013Caisse Nationale de l'Assurance Maladie, Paris, France"},{"name":"Epid\u00e9miologie en Dermatologie et Evaluation des Th\u00e9rapeutiques, Universit\u00e9 Paris\u2013Est Creteil, Cr\u00e9teil, France"},{"name":"D\u00e9partement de Dermatologie, Assistance Publique\u2013H\u00f4pitaux de Paris, H\u00f4pitaux universitaires Henri Mondor, Universit\u00e9 Paris\u2013Est Creteil, Cr\u00e9teil, France"},{"name":"INSERM, Centre d\u2019Investigation Clinique 1430, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"12","key":"doi210034r1","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1111\/jdv.13354","article-title":"European S3-Guidelines on the systemic treatment of psoriasis vulgaris: update 2015: short version-EDF in cooperation with EADV and IPC.","volume":"29","author":"Nast","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"doi210034r2","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.","volume":"1","author":"Sbidian","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"doi210034r3","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview.","volume":"CD008794","author":"Singh","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"doi210034r4","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1016\/j.jid.2016.03.035","article-title":"Risk of serious infections in patients with psoriasis on biologic therapies: a systematic review and meta-analysis.","volume":"136","author":"Yiu","year":"2016","journal-title":"J Invest Dermatol"},{"issue":"3","key":"doi210034r5","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/bjd.v184.3","article-title":"Meta-analysis results do not reflect the real safety of biologics in psoriasis.","volume":"184","author":"Afach","year":"2021","journal-title":"Br J Dermatol."},{"issue":"4","key":"doi210034r6","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1001\/archdermatol.2011.2768","article-title":"Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials.","volume":"148","author":"Garcia-Doval","year":"2012","journal-title":"Arch Dermatol"},{"issue":"5","key":"doi210034r7","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1001\/jamadermatol.2018.0183","article-title":"Comparison of drug discontinuation, effectiveness, and safety between clinical trial eligible and ineligible patients in BADBIR.","volume":"154","author":"Mason","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"2","key":"doi210034r8","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/jdv.v34.2","article-title":"Users of biologics in clinical practice: would they be eligible for phase III clinical studies? cohort study in the French Psoriasis Registry PSOBIOTEQ.","volume":"34","author":"Masson Regnault","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"doi210034r9","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.jid.2016.08.034","article-title":"Infections in moderate to severe psoriasis patients treated with biological drugs compared to classic systemic drugs: findings from the BIOBADADERM Registry.","volume":"137","author":"D\u00e1vila-Seijo","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"9","key":"doi210034r10","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamadermatol.2015.0718","article-title":"Risk of serious infection with biologic and systemic treatment of psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR).","volume":"151","author":"Kalb","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"10","key":"doi210034r11","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1001\/jamadermatol.2019.1121","article-title":"Risk of serious infection in patients receiving systemic medications for the treatment of psoriasis.","volume":"155","author":"Dommasch","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"3","key":"doi210034r12","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/(ISSN)1099-1557","article-title":"Immortal time bias in observational studies of drug effects.","volume":"16","author":"Suissa","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"doi210034r13","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1136\/annrheumdis-2019-216102","article-title":"Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis.","volume":"79","author":"Li","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"doi210034r14","doi-asserted-by":"crossref","first-page":"i2002","DOI":"10.1136\/bmj.i2002","article-title":"Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort study.","volume":"353","author":"Weill","year":"2016","journal-title":"BMJ"},{"issue":"5","key":"doi210034r15","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1093\/eurpub\/ckq108","article-title":"Hospitalization admission rates for low-income subjects with full health insurance coverage in France.","volume":"21","author":"Tuppin","year":"2011","journal-title":"Eur J Public Health"},{"key":"doi210034r16","doi-asserted-by":"publisher","first-page":"S149","DOI":"10.1016\/j.respe.2017.05.004","article-title":"Value of a national administrative database to guide public decisions: from the syst\u00e8me national d\u2019information interr\u00e9gimes de l\u2019Assurance Maladie (SNIIRAM) to the syst\u00e8me national des donn\u00e9es de sant\u00e9 (SNDS) in France.","volume":"65","author":"Tuppin","year":"2017","journal-title":"Rev Epidemiol Sante Publique"},{"issue":"17","key":"doi210034r17","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1001\/jama.2017.16071","article-title":"Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease.","volume":"318","author":"Lemaitre","year":"2017","journal-title":"JAMA"},{"issue":"2","key":"doi210034r18","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1053\/j.gastro.2018.04.012","article-title":"Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases.","volume":"155","author":"Kirchgesner","year":"2018","journal-title":"Gastroenterology"},{"issue":"1","key":"doi210034r19","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/bjd.2019.180.issue-1","article-title":"Persistence of treatment with biologics for patients with psoriasis: a real-world analysis of 16 545 biologic-na\u00efve patients from the French National Health Insurance database (SNIIRAM).","volume":"180","author":"Sbidian","year":"2019","journal-title":"Br J Dermatol"},{"issue":"2","key":"doi210034r20","doi-asserted-by":"publisher","first-page":"99","DOI":"10.7326\/M18-1512","article-title":"Effectiveness and safety of reference infliximab and biosimilar in crohn disease: a French equivalence study.","volume":"170","author":"Meyer","year":"2019","journal-title":"Ann Intern Med"},{"issue":"3","key":"doi210034r21","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/bjd.v182.3","article-title":"Persistence of apremilast in moderate-to-severe psoriasis: a real-world analysis of 14 147 apremilast- and methotrexate-naive patients in the French National Health Insurance database.","volume":"182","author":"Sbidian","year":"2020","journal-title":"Br J Dermatol"},{"issue":"9596","key":"doi210034r22","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"issue":"3","key":"doi210034r23","article-title":"Topical treatments for chronic plaque psoriasis.","volume":"CD005028","author":"Mason","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"doi210034r24","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1038\/jid.2015.208","article-title":"Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).","volume":"135","author":"Warren","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"2","key":"doi210034r25","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1524-4733.2009.00671.x","article-title":"Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals.","volume":"13","author":"Xu","year":"2010","journal-title":"Value Health"},{"issue":"2","key":"doi210034r26","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/bjd.2019.180.issue-2","article-title":"Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR).","volume":"180","author":"Yiu","year":"2019","journal-title":"Br J Dermatol"},{"issue":"5","key":"doi210034r27","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.jaad.2017.07.047","article-title":"Serious infections among a large cohort of subjects with systemically treated psoriasis.","volume":"77","author":"Dobry","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"doi210034r28","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12529","article-title":"Rate of serious infection in patients who are prescribed systemic biologic or nonbiologic agents for psoriasis: a large, single center, retrospective, observational cohort study.","volume":"30","author":"Carneiro","year":"2017","journal-title":"Dermatol Ther"},{"issue":"12","key":"doi210034r29","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1111\/jdv.2017.31.issue-12","article-title":"Factors associated with the choice of the first biologic in psoriasis: real-life analysis from the Psobioteq cohort.","volume":"31","author":"Sbidian","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"doi210034r30","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1111\/bjd.2017.177.issue-3","article-title":"Identification of factors that may influence the selection of first-line biological therapy for people with psoriasis: a prospective, multicentre cohort study.","volume":"177","author":"Davison","year":"2017","journal-title":"Br J Dermatol"},{"issue":"3","key":"doi210034r31","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1111\/bjd.2013.169.issue-3","article-title":"Systemic psoriasis therapy shows high between-country variation: a sign of unwarranted variation? cross-sectional analysis of baseline data from the PSONET registries.","volume":"169","author":"Garcia-Doval","year":"2013","journal-title":"Br J Dermatol"},{"key":"doi210034r32","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1016\/j.cmi.2018.02.002","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors).","volume":"24","author":"Winthrop","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"doi210034r33","doi-asserted-by":"crossref","DOI":"10.1002\/acr.24630","article-title":"Risk of hospitalized serious infection after initiating ustekinumab or other biologics for psoriasis or psoriatic arthritis.","author":"Jin","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10281","key":"doi210034r34","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis.","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"doi210034r35","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/JID.2015.350","article-title":"Risk of multiple sclerosis in patients with psoriasis: a Danish nationwide cohort study.","volume":"136","author":"Egeberg","year":"2016","journal-title":"J Invest Dermatol"},{"issue":"6","key":"doi210034r36","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1080\/14737167.2018.1512408","article-title":"Adherence and resource use among psoriasis patients treated with biologics.","volume":"18","author":"Aleshaki","year":"2018","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"7","key":"doi210034r37","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/pds.v25.7","article-title":"Positive predictive values of selected hospital discharge diagnoses to identify infections responsible for hospitalization in the French national hospital database.","volume":"25","author":"Sahli","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2782062\/jamadermatology_penso_2021_oi_210034_1631232145.55929.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T15:33:55Z","timestamp":1631720035000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2782062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,1]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2021.2599","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9,1]]}}}